| Literature DB >> 22176611 |
Hedda Tschudi-Madsen1, Mona Kjeldsberg, Bård Natvig, Camilla Ihlebaek, Ingvild Dalen, Yusman Kamaleri, Jørund Straand, Dag Bruusgaard.
Abstract
BACKGROUND: There is a lack of knowledge about the pattern of symptom reporting in the general population as most research focuses on specific diseases or symptoms. The number of musculoskeletal pain sites is a strong predictor for disability pensioning and, hence, is considered to be an important dimension in symptom reporting. The simple method of counting symptoms might also be applicable to non-musculoskeletal symptoms, rendering further dimensions in describing individual and public health. In a general population, we aimed to explore the association between self-reported non-musculoskeletal symptoms and the number of pain sites.Entities:
Mesh:
Year: 2011 PMID: 22176611 PMCID: PMC3310803 DOI: 10.1186/1471-2474-12-285
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Prevalence of number of pain sites (NPS) by gender
| NPS | Men (N = 1455) | Women (N = 1772) | Total (N = 3227) |
|---|---|---|---|
| %(95%CI) | %(95%CI) | %(95%CI) | |
| 38.4 (36.2 to 41.2) | 23.2 (21.3 to 25.2) | 30.1 (28.5 to 31.7) | |
| 18.2 (16.3 to 20.3) | 15.7 (14.1 to 17.5) | 16.8 (15.5 to 18.1) | |
| 12.4 (10.8 to 14.2) | 14.6 (13.0 to 16.3) | 13.5 (12.4 to 14.8) | |
| 12.8 (11.2 to 14.6) | 13.0 (11.6 to 14.7) | 12.9 (11.8 to 14.1) | |
| 7.7 (6.4 to 9.2) | 10.7 (9.31 to 12.2) | 9.3 (8.3 to 10.4) | |
| 4.5 (3.5 to 5.7) | 7.7 (6.5 to 9.0) | 6.2 (5.4 to 7.1) | |
| 3.0 (2.3 to 4.1) | 5.6 (4.6 to 6.8) | 4.4 (3.8 to 5.2) | |
| 1.2 (0.7 to 1.9) | 4.2 (3.3 to 5.2) | 2.8 (2.3 to 3.5) | |
| 0.7 (0.4 to 1.3) | 2.1 (1.6 to 2.9) | 1.5 (1.1 to 2.0) | |
| 0.8 (0.4 to 1.4) | 1.7 (1.2 to 2.4) | 1.3 (0.9 to 1.7) | |
| 0.8 (0.4-1.4) | 1.6 (1.1 to 2.3) | 1.2 (0.9 to 1.7) | |
NPS Number of pain sites: CI Confidence Interval
Prevalence of number of non-muscular symptoms (NN-MS) by gender
| NN-MS | Men (N = 1455) | Women (N = 1772) | Total (N = 3227) |
|---|---|---|---|
| % (95% CI) | % (95% CI) | % (95% CI) | |
| 16.8 (15.0 to 18.8) | 9.9 (8.6 to 11.4) | 13.0 (11.9 to 14.2) | |
| 14.7(13.0 to 16.7) | 12.4 (11.0 to 14.0) | 13.4 (12.3 to 14.6) | |
| 14.1 (12.4 to 16.0) | 15.1 (13.5-16.9) | 14.6 (13.5 to 15.9) | |
| 13.6 (11.9 to 15.4) | 11.9 (10.4 to 13.4) | 12.6 (11.5 to 13.8) | |
| 12.0 (10.5 to 13.8) | 11.6 (10.2 to 13.2) | 11.8 (10.7 to 13.0) | |
| 8.7 (7.4 to 10.3) | 11.1 (9.7 to 12.7) | 10.0 (9.0 to 11.1) | |
| 7.1 (5.8 to 8.5) | 7.6 (6.4 to 8.9) | 7.3 (6.5 to 8.3) | |
| 5.8 (4.7 to 7.2) | 7.5 (6.4 to 8.8) | 6.7 (5.9 to 7.6) | |
| 2.8 (2.0 to 3.8) | 5.1 (4.2 to 6.2) | 4.0 (3.4 to 4.8) | |
| 2.1 (1.5 to 3.0) | 3.1 (2.3 to 4.0) | 2.6 (2.1 to 3.2) | |
| 1.7 (1.2 to 2.6) | 2.3 (1.7 to 3.1) | 2.1 (1.6 to 2.6) | |
| 0.6 (0.3 to 1.1) | 1.5 (1.0 to 2.2) | 1.1 (0.8 to 1.5) | |
| 0.6 (0.3 to 1.2) | 0.7 (0.4 to 1.39 | 0.7 (0.4 to 1.0) | |
| 0.1 (<0.0 to 0.4) | 0.2 (0.03 to 0.5) | 0.1 (0.04 to 0.33) | |
NN-MS Number of non-muscular symptoms; CI Confidence Interval
Prevalence of total symptoms (number of pain sites (NPS) + number of non-muscular symptoms (NN-MS)) by gender
| Total symptoms | Men (N = 1455) | Women (N = 1772) | Total (N = 3227) |
|---|---|---|---|
| (NPS+ NN-MS) | % (95% CI) | % (95% CI) | % (95% CI) |
| 11.5 (9.9 to 13.2) | 5.4 (4.4 to 6.5) | 8.1 (7.2 to 9.1) | |
| 11.7 (10.2 to 13.5) | 8.0 (6.8 to 9.4) | 9.7 (8.7 to 10.7) | |
| 9.6 (8.1 to 11.2) | 9.4 (8.1 to 10.4) | 9.4 (8.5 to 10.5) | |
| 11.2 (9.6 to 12.9) | 7.5 (6.4 to 8.8) | 9.1 (8.2 to 10.2) | |
| 9.1 (7.8 to 10.7) | 8.7 (7.5 to 10.1) | 8.9 (7.9 to 9.9) | |
| 8.4 (7.1 to 9.9) | 7.8 (6.7 to 9.2) | 8.1 (7.2 to 9.1) | |
| 6.9 (5.7 to 8.3) | 7.2 (6.1 to 8.5) | 7.0 (6.2 to 8.0) | |
| 6.4 (5.3 to 7.8) | 7.2 (6.1 to 8.5) | 6.8 (6.0 to 7.7) | |
| 5.3 (4.3 to 6.6) | 6.1 (5.1 to 7.4) | 5.8 (5.0 to 6.6) | |
| 4.4 (3.4 to 5.6) | 4.9 (3.9 to 6.0) | 4.6 (3.9 to 5.4) | |
| 4.7 (3.7 to 5.9) | 5.6 (4.7 to 6.8) | 5.2 (4.5 to 6.0) | |
| 3.1 (2.3 to 4.2) | 4.7 (3.8 to 5.8) | 4.0 (3.3 to 4.7) | |
| 2.2 (1.5 to 3.0) | 4.0 (3.1 to 5.0) | 3.1 (2.6 to 3.8) | |
| 2.1 (1.5 to 3.0) | 3.6 (2.8 to 4.6) | 2.9 (2.4 to 3.6) | |
| 1.3 (1.8 to 2.1) | 2.1 (1.5 to 2.9) | 1.7 (1.3 to 2.3) | |
| 1.8 (0.5 to 1.5) | 2.5 (1.8 to 3.3) | 1.7 (1.3 to 2.3) | |
| 0.7 (0.4 t 1.3) | 1.6 (1.1 to 2.3) | 1.2 (0.9 to 1.6) | |
| 0.6 (0.3 to 1.2) | 1.6 (1.1 to 2.4) | 1.2 (0.9 to 1,6) | |
| 0.1 (0-0.5) | 0.9 (0.5 to 1.5) | 0.6 (0.4 to 0.9) | |
| 0.4 (0.1 to 0.8) | 0.4 (0.2 to 0.8) | 0.4 (0.2 to 0.7) | |
| 0.1 (0 to 0.5) | 0.2 (0.1 to 0.6) | 0.2 (0.1 to 0.4) | |
| 0 (0 to0.2) | 0.4 (1.2 to 0.8) | 0.2 (0.1 to 0.5) | |
| 0.1 (0 to 0.5) | 0.2 (0.1 to 0.6) | 0.2 (0.1 to 0.4) | |
| 0 (0 to 0.2) | 0 (0 to 0.2) | 0 (0 to 0.1) | |
NPS Number of pain sites; NN-MS Number of non-muscular symptoms; CI Confidence Interval
Figure 1The association between the number of non-musculoskeletal symptoms (NN-MS) and the number of pain sites (NPS). The figure is based on the mean NN-MS score for each NPS-score.
Linear regression analyses of the association between number of pain sites (NPS) and individual non-muscular symptoms
| Model II1 | Model III2 | |||||||
|---|---|---|---|---|---|---|---|---|
| 1.33 | (1.14-1.52) | 0.051 | <0.001 | 0.22 | (0.03-0.40) | 0.001 | 0.020 | |
| 1.76 | (1.56-1.96) | 0.078 | <0.001 | 0.51 | (0.31-0.72) | 0.005 | <0.001 | |
| 1.78 | (1.58-1.98) | 0.081 | <0.001 | 0.53 | (0.33-0.73) | 0.005 | <0.001 | |
| 1.08 | (0.91-1.25) | 0.044 | <0.001 | 0.20 | (0.05-0.36) | 0.001 | 0.12 | |
| 1.67 | (1.49-1.85) | 0.085 | <0.001 | 0.51 | (0.33-0.70) | 0.006 | <0.001 | |
| 1.10 | (0.93-1.27) | 0.043 | <0.001 | 0.35 | (0.20-0.51) | 0.004 | <0.001 | |
| 1.34 | (1.10-1.57) | 0.035 | <0.001 | 0.43 | (0.22-0.64) | 0.003 | <0.001 | |
| 0.93 | (0.73-1.13) | 0.024 | <0.001 | 0.40 | (0.22-0.57) | 0.004 | <0.001 | |
| 1.52 | (1.36-1.68) | 0.093 | <0.001 | 0.43 | (0.28-0.59) | 0.006 | <0.001 | |
| 1.86 | (1.69-2.03) | 0.120 | <0.001 | 0.78 | (0.61-0.95) | 0.017 | <0.001 | |
| 1.63 | (1.45-1.82) | 0.080 | <0.001 | 0.26 | (0.05-0.47) | 0.001 | 0.14 | |
| 1.51 | (1.35-1.68) | 0.089 | <0.001 | 0.31 | (0.12-0.49) | 0.002 | 0.001 | |
| 1.57 | (1.41-1.72) | 0.104 | <0.001 | 0.74 | (0.59-0.89) | 0.019 | <0.001 | |
β unstandardised regression coefficient; R2 multiple correlation coefficient
1 Model II: Dependent variable: Number of pain sites (NPS). Independent variable: Individual non-muscular symptoms while controlling for age and gender
2 Model III: Dependent variable: Number of pain sites (NPS). Independent variable: individual non-muscular symptoms while controlling for the remaining 12 non-muscular symptoms in addition to age and gender
Figure 2The number of pain sites (NPS) in relation to the three non-musculoskeletal symptoms with the highest explanatory power in NPS (dizziness, sleep problems, and tiredness) and the three non-musculoskeletal symptoms with the lowest explanatory power in NPS (diarrhoea, constipation, and eczema). The figure is based on the mean score of the symptoms for each NPS-score.